Active Ingredient: ABILIFY
Aripiprazole significantly decreased the mean ΔQTc interval compared with placebo (MD = −0.73 ms, 95 % CI (−0.87, −0.6 ms), p < 0.00001) and active controls (MD = −4.33 ms, 95 % CI (−6.72, −1.94 ms), p = 0.0004). In total, 31 randomized controlled trials reported at least one dichotomous QTc data point that could be pooled to generate a forest plot of aripiprazole compared with placebo (Fig. 3a) and active controls (i.e., chlorpromazine, clozapine, fluphenazine, haloperidol, olanzapine, perospirone, perphenazine, quetiapine, risperidone, sulpiride, ziprasidone, and the benzodiazepine lorazepam) (Fig. 3b). Study heterogeneity was also not significant in this analysis indicating similar observed effects on the QTc interval among the studies (I 2 = 0 %, p = 0.82). No significant subgroup difference was found between placebo and active controls (p = 0.2), and there was no difference in QTc prolongation risk between aripiprazole and placebo (RR = 0.85, 95 % CI (0.51, 1.43), p = 0.54), although there was a significant difference when comparing with active controls (RR = 0.53, 95 % CI (0.32, 0.88), p = 0.01). Polcwiartek, C., Sneider, B., Graff, C. et al. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology 232, 3297–3308 (2015). https://doi.org/10.1007/s00213-015-4024-9
https://doi.org/10.1007/s00213-015-4024-9